



File No. BIO/CT/21/000082

Dated 31-May-2022

To,

M/s Veeda Clinical Research Private Limited,
Shivalik Plaza-A Near I.I.M., Ambawadi ,
Ahmedabad (India) - 380015.

Subject: Application for grant of permission to conduct Phase I(PK/PD) clinical trial entitled –“ A Randomized, Double Blind, Two-Arm, Parallel Group, Single Dose Comparative PK, PD and Immunogenicity Study Comparing ADL-018 Lyophilized Powder With US-Licensed Xolair Lyophilized powder Administered Through Subcutaneous Route In healthy Adult Subjects” as per Protocol No.: OMA/2020/1772, Version 5.0 Date: 29.03.2022 – regarding

Ref.:Your Application No. BIO/CT04/FF/2021/26620 dated 25-06-2021

Sir,

With reference to your Application No. BIO/CT04/FF/2021/26620 dated 25-06-2021, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.

Yours faithfully,

VENUGOPAL G SOMANI
Drugs Controller General (India)

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=DRUGS
CONTROLLER GENERAL (INDIA),
pseudonym=1*12040a34e2f727ba2b2557487
3229561749078951e66869c43b58748ee3113
c, postalCode=110002, st=Delhi,
serialNumber=e97f241aa0c0bba41522525ffca
0705074b4997e6b2f4b5c8d81cf282adeaf5d,
cn=VENUGOPAL G SOMANI
Date: 2022.05.31 18:13:45 +05'30'

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

The Central Licencing Authority hereby permits **M/s Veeda Clinical Research Private Limited**, Shivalik Plaza-A Near I.I.M., Ambawadi ,Ahmedabad (India) - 380015, to conduct clinical trial of the new drug or investigational new drug study titled "A Randomized, Double Blind, Two-Arm, Parallel Group, Single Dose Comparative PK, PD and Immunogenicity Study Comparing ADL-018 Lyophilized Powder With US-Licensed Xolair Lyophilized powder Administered Through Subcutaneous Route In Healthy Adult Subjects" as per Protocol No.: OMA/2020/1772, Version 5.0 Date: 29.03.2022 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: 31.05.2022

VENUGOPAL G SOMANI
(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licensing Authority

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=DRUGS
CONTROLLER GENERAL (INDIA),
pseudoym=12046a84e31727bacb25574
8732c456d249073e55e953d9cb5b58748ee
3113c, postalCode=110002, st=DELHI,
serialNumber=e97f241aad0bba41522525f
fca0705074b4997e6b2f4b5c8d81cf282adea
f5d, cn=VENUGOPAL G SOMANI
Date: 2022.05.31 18:13:57 +05'30'

Annexure:**Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug	Omalizumab (r-DNA origin) injection															
Therapeutic class	Antiasthmatic(Monoclonal antibodies)															
Dosage form:	Lyophilized powder in vial for injection(single use vial)															
Composition:	<table><tr><th>Name of Ingredient</th><th>Quantity/ per vial*</th></tr><tr><td>Omalizumab (r-DNA Origin) (ADL-018) In-house</td><td>202.5mg</td></tr><tr><td>L-Histidine.... FCC</td><td>1.8mg</td></tr><tr><td>L-Histidine hydrochloride monohydrate...USP</td><td>2.8mg</td></tr><tr><td>Polysorbate 20... USP</td><td>0.5mg</td></tr><tr><td>Sucrose.....NF</td><td>145.5mg</td></tr><tr><td colspan="2">(* To be reconstituted with 1.4ml sterile water for injection USP)</td></tr></table>		Name of Ingredient	Quantity/ per vial*	Omalizumab (r-DNA Origin) (ADL-018) In-house	202.5mg	L-Histidine.... FCC	1.8mg	L-Histidine hydrochloride monohydrate...USP	2.8mg	Polysorbate 20... USP	0.5mg	Sucrose.....NF	145.5mg	(* To be reconstituted with 1.4ml sterile water for injection USP)	
Name of Ingredient	Quantity/ per vial*															
Omalizumab (r-DNA Origin) (ADL-018) In-house	202.5mg															
L-Histidine.... FCC	1.8mg															
L-Histidine hydrochloride monohydrate...USP	2.8mg															
Polysorbate 20... USP	0.5mg															
Sucrose.....NF	145.5mg															
(* To be reconstituted with 1.4ml sterile water for injection USP)																
Indications:	Asthma, Chronic Idiopathic Urticaria, Nasal Polyps															

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Veeda Clinical Research Limited, 2 nd , 3 rd , 4 th floor, Shivalik Plaza, Near I.I.M., Ambawadi, Ahmedabad-380015, Gujarat, India Phone: +91-79-67773000	Sangini Hospital Ethics Committee C/o Sangini Hospital, 1 st Floor, Santorini Square, B/h Abhishree Complex, Opp. Star Bazar, Nr. Jodhpur Cross Roads, Satellite, Ahmedabad-380015, Gujarat, India Telephone: 07940056171 EC Reg. No. ECR/147/Inst/GJ/2013/RR-19	Dr Hiren Prajapati, MD (Pharmacology)
2	Veeda Clinical Research Limited, Office No. 9, 10 & 11-1 st , 2 nd and 3 rd Floor, Radhe Palladium, Panchot, Mehsana, Gujarat – 384205, India	Shreenidhi Heart and Medical Hospital Ethics Committee, C/o Shreenidhi Heart & Medical Hospital, 1 st Floor, Opposite Panchmahadev's Temple, Jail Road, Mehsana-384 002, Gujarat, India. EC Reg. No. ECR/1087/Inst/GJ/2018/RR-21	Dr. Sunil Soitawala, MD (Pharmacology)